Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (2216)	7/15/1999 11:47:00 PM
From: BDR	Read Replies (1) \| Respond to of 10293

<TAP Holdings' Uprima, the only central nervous system drug for sexual dysfunction currently under development, expected to be on the market in the second half of 2000. A few months later, Zonagen (Nasdaq: ZONA - news)/Schering-Plough's (NYSE: SGP - news) Vasomax, already sold in some countries outside the United States, should join the group.> Where does the Wall Street Transcript get the idea that Vasomax will ever get approved? And have they checked into those "sales" in other countries. Last I heard the number was very close to zero.